The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $54.71

Today's change-1.14 -2.04%
Updated May 3 4:02 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $54.71

Today's change-1.14 -2.04%
Updated May 3 4:02 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S crosses below 200-day moving average

Novo Nordisk A/S closed sharply lower Tuesday, dropping (U.S.)$1.14 or 2.04% to (U.S.)$54.71 and crossing below its 200-day moving average. Over the last five days, shares have lost 0.92% and are down 5.80% for the last year to date. This security has underperformed the S&P 500 by 2.16% during the last year.

Key company metrics

  • Open(U.S.) $55.25
  • Previous close(U.S.) $55.85
  • High(U.S.) $55.47
  • Low(U.S.) $54.60
  • Bid / Ask-- / --
  • YTD % change-5.80%
  • Volume885,161
  • Average volume (10-day)1,012,404
  • Average volume (1-month)1,041,175
  • Average volume (3-month)1,427,324
  • 52-week range(U.S.) $46.17 to (U.S.) $60.34
  • Beta0.78
  • Trailing P/E26.11×
  • P/E 1 year forward24.50×
  • Forward PEG2.09×
  • Indicated annual dividend(U.S.) $0.96
  • Dividend yield1.75%
  • Trailing EPS(U.S.) $2.10
Updated May 3 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+32.30%

Based on its net profit margin of 32.30%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.14%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue28,87626,79227,05925,200
Total other revenue--------
Total revenue28,87626,79227,05925,200
Gross profit24,26822,94523,20021,326
Total cost of revenue4,6083,8473,8593,874
Total operating expense17,75114,81214,57711,343
Selling / general / administrative9,2037,9038,0627,001
Research & development4,0343,2893,0353,250
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)000-2,376
Other operating expenses, total-94-227-379-406
Operating income11,12511,98012,48213,857
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax10,31410,13610,54812,485
Income after tax8,2588,3838,3439,876
Income tax, total2,0561,7532,2052,609
Net income8,2588,3838,3439,876
Total adjustments to net income--------
Net income before extra. items8,2588,3838,3439,876
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items8,2588,3838,3439,876
Inc. avail. to common incl. extra. items8,2588,3838,3439,876
Diluted net income8,2588,3848,3439,876
Dilution adjustment--1----
Diluted weighted average shares2,5512,5722,5842,604
Diluted EPS excluding extraordinary itemsvalue per share3.243.263.233.79
Dividends per sharevalue per share5.220.000.000.00
Diluted normalized EPSvalue per share3.243.263.233.07